Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA47 - Sep 02 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA871 – March 2023 Hospital Eptotermin alfa () NHSE Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Erectile dysfunction drugs (Various) ICB Erectile dysfunction - limited categories of patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Erectile dysfunction drugs (Various) ICB Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLUE Erenumab Aimovig® ICB Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA682 – March 2021 ADVICE Ergocalciferol / Vitamin D Injections ICB Vitamin D deficiency Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 Hospital Eribulin (Halaven®) NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515 Not commissioned. No NHS prescribing in primary or secondary care TA515 - Mar 18 BLACK Erlotinib (Tarceva®) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per NICE TA 227 and NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 Hospital Erlotinib (Tarceva®) NHSE First-line treatment of locally advanced or metastatic EGFR-TK mutation- positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 Hospital Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Hospital Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion-dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Erythropoietin / Epoetin (Eprex®, NeoRecormon ® and others) NHSE Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG114 - Nov 11 Double Red Erythropoietin / Epoetin (Eprex®, NeoRecormon ® and others) ICB Anaemia in renal failure pre-dialysis. Not recommended for routine use NG8 - Jun 15
Breach by Licensee a. The licensee shall have five (5) business days from its receipt of written notice by Producer and/or Producer’s authorized representative to cure any alleged breach of this Agreement by Licensee. Licensee’s failure to cure the alleged breach within five (5) business days shall result in Licensee’s default of its obligations, its breach of this Agreement, and at Producer's sole discretion, the termination of Licensee’s rights hereunder.
By Licensee Except for claims for which Oracle is obligated to indemnify Licensee under Section 7.2, Licensee shall defend, at Licensee's expense, any and all claims brought against Oracle, and shall pay all damages awarded by a court of competent jurisdiction, or such settlement amount negotiated by Licensee, arising out of or in connection with Licensee's reproduction, development or distribution of product(s) developed using the TCK. Licensee's obligation to provide a defense under this Section 7.5 shall arise provided that Oracle: (a) provides notice of the claim promptly to Licensee; (b) gives Licensee sole control of the defense and settlement of the claim; (c) provides to Licensee, at Licensee's expense, all available information, assistance and authority to defend; and (d) has not compromised or settled such proceeding without Licensee's prior written consent.
SOFTWARE LICENSE GRANT Where Product is acquired on a licensed basis the following shall constitute the license grant:
Developer License We grant you a non-assignable, non-sublicensable, non-exclusive, worldwide right and license for the number of Developer(s) indicated in the Order Form to install the Software on any number of Machines in order to internally use the Software to create, develop and test Applications. For clarity, a single Software license may be re-allocated to another Developer in the event that the original Developer is no longer employed by you or has been assigned to a new role where access to the Software will no longer be required on a permanent basis.
